Zosyn Articles
Profit drop for Taisho, but firm sees recovery
5 June 2009
Wyeth's first-quarter 2009 profit flat year-on-year as it prepares for Pfizer mega-merger
29 April 2009
Wyeth's 3rd-qtr profit flat; AD drug delayed
3 November 2008
Japan stock market week to Oct 13, 2008
20 October 2008
Wyeth beats forecasts despite generics
5 May 2008
Wyeth's 2nd-qtr net income climbs 12.5%
30 July 2007
Wyeth's 1st-qtr income up 12% to $1.25B
30 April 2007
Patent expiry will "constrain" antibacterial market
15 January 2007
Wyeth 1st-qtr earnings rocket 44%
25 April 2005
Fen-phem charges gouge Wyeth results
7 February 2005
Wyeth's 2nd-qtr profit slips, but sales climb
26 July 2004
Wyeth posts 9% rise in 1st-qtr revenue
3 May 2004
Wyeth's Zosyn dosing cut
5 May 2003
Indian firms to launch new drugs this fiscal year
29 August 2000
AHP posts 18% net income growth
20 April 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
FDA Approvals In Brief
11 March 1998
AHP Bid For Cyanamid Will Broaden Product Range
15 August 1994
IMPROVED 1st QTR FOR CYANAMID
25 April 1994
BAD NEW FOR MEDIMMUNE AS RESPIGAM STUMBLES
13 December 1993
LEDERLE'S ZOSYN LAUNCHED IN USA
22 November 1993
LEDERLE'S ZOSYN GAINS US APPROVAL
1 November 1993
COPROMOTION DEAL FOR RESPIVIR, ZOSYN
26 July 1993
Showing 1-27 of 27 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
